

Appendix B

Table 1: Nephropathy Status at enrollment according to study group.

Characteristic		Case			Control		
		Singleton	Trio Proband	Total	Singleton	Trio Proband	Total
ESRD							
N		369 (65%)	127 (51%)	496 (60%)	0	0	0
Dialysis		40 (11%)	8 (6%)	48 (10%)			
Kidney Transplant		327 (89%)	119 (94%)	446 (90%)			
Diabetes Duration at ESRD							
(years)	<i>Mean (SD)</i>	24.6 (7.1)	24.5 (6.8)	24.5 (7.0)			
ESRD Duration at Enrollment							
(years)	<i>Mean (SD)</i>	9.1 (5.5)	7.6 (5.4)	8.7 (5.5)			
NON-ESRD							
N		203 (35%)	121 (49%)	324 (40%)	595 (100%)	302 (100%)	891 (100%)
ACR (ug albumin/mg creatinine)							
	<i>Median (SD)</i>	1045 (1577)	1083 (1292)	1061 (1475)	5.8 (3.5)	5.8 (3.6)	5.8 (3.6)
MDRD GFR (mL/min/1.73m2)*							
	<i>Mean (SD)</i>	53.7 (27)	49.6 (24.7)	52.3 (26.3)	87.1 (16.8)	87.9 (15.8)	87.4 (16.5)
	<i>GFR<60</i>	122 (62%)	68 (62%)	190 (62%)	19 (3%)	3 (1%)	22 (3%)
	<i>GFR≥60</i>	74 (38%)	41 (38%)	115 (38%)	562 (97%)	291 (99%)	853 (97%)
Cockcroft-Gault GFR (mL/min)*							
	<i>Mean (SD)</i>	72.1 (35.1)	67.5 (36.7)	70.5 (35.7)	108 (31)	114 (30)	110 (31)
	<i>GFR<60</i>	84 (44%)	54 (50%)	138 (46%)	7 (1%)	3 (1%)	10 (1%)
	<i>GFR≥60</i>	109 (56%)	55 (50%)	164 (54%)	566 (99%)	283 (99%)	849 (99%)
Serum Creatinine (mg/dL)							
	<i>Mean (SD)</i>	1.8 (1.1)	1.8 (1.0)	1.8 (1.05)	0.9 (0.2)	0.9 (0.1)	0.9 (0.2)
100/creatinine	<i><60</i>	86 (44%)	48 (44%)	134 (44%)	0 (0%)	0 (0%)	0 (0%)
	<i>≥60</i>	110 (56%)	61 (56%)	171 (56%)	579 (100%)	292 (100%)	871 (100%)
Serum Cystatin C (mg/dL)							
	<i>Mean (SD)</i>	1.8 (0.9)	1.8 (1.0)	1.8 (0.9)	0.9 (0.2)	0.9 (0.2)	0.9 (0.2)
100/cystatin C	<i><60</i>	83 (43%)	50 (47%)	133 (45%)	2 (0.4%)	0 (0%)	2 (0.2%)
	<i>≥60</i>	109 (57%)	56 (53%)	165 (55%)	554 (99.6%)	277 (100%)	831 (99.8%)

* References 41 and 42.

Table 2: Clinical characteristics at enrollment according to study group.

Characteristic		Case			Control			P value
		Singleton	Trio Proband	Total	Singleton	Trio Proband	Total	Total Cases vs. Total Controls
Race								
	<i>White</i>	505 (89%)	234 (94%)	739 (90%)	571 (97%)	292 (97%)	863 (97%)	<0.0001
Gender								
	<i>Male</i>	305 (54%)	106 (43%)	411 (50%)	241 (41%)	127 (42%)	368 (41%)	0.0002
Age at Entry (years)								
	<i>Mean (SD)</i>	43.2 (6.8)	39.6 (7.2)	42.2 (7.1)	39.9 (8.4)	34.8 (8.2)	38.2 (8.7)	<0.0001
	<i><40</i>	174 (31%)	143 (58%)	317 (39%)	291 (49%)	218 (73%)	509 (57%)	<0.0001
	<i>40+</i>	396 (69%)	105 (42%)	501 (61%)	302 (51%)	82 (27%)	384 (43%)	
Body Mass Index (kg/m²)								
	<i>Mean (SD)</i>	25.9 (5.4)	25.5 (7.2)	25.8 (5.4)	26.1 (4.4)	26.5 (4.5)	26.2 (4.4)	0.0004
Waist Circumference (cm)								
	<i>Mean (SD)</i>	89.1 (15.8)	89.1 (14.6)	89.1 (15.5)	86.8 (13.9)	84.3 (12.5)	85.9 (13.5)	0.02
Smoker								
	<i>Ever</i>	281 (49%)	113 (46%)	394 (48%)	201 (34%)	96 (32%)	297 (33%)	<0.0001

Table 3: Diabetes characteristics at enrollment according to study group.

Characteristic		Case			Control			P value
		Singleton	Trio Proband	Total	Singleton	Trio Proband	Total	Total Cases vs. Total Controls
Age at Diagnosis of Diabetes								
	<i>Mean (SD)</i>	12.2 (6.9)	10.5 (5.8)	11.7 (6.6)	12.8 (7.3)	13.6 (7.5)	11.2 (6.6)	0.0046
	<i>0-9</i>	216 (38%)	117 (47%)	333 (41%)	202 (34%)	130 (43%)	332 (37%)	0.003
	<i>10-14</i>	173 (30%)	77 (31%)	250 (31%)	136 (23%)	100 (33%)	236 (26%)	
	<i>15+</i>	181 (32%)	54 (22%)	235 (29%)	255(43%)	70 (23%)	325 (36%)	
Diabetes Duration								
	<i>Mean (SD)</i>	31.0 (8.2)	29.1 (7.3)	30.4 (8.0)	26.3 (7.9)	23.6 (7.1)	25.4 (7.7)	<0.0001
	<i>10-14</i>	11 (2%)	4 (2%)	15 (2%)	NA	NA	NA	<0.0001
	<i>15-24</i>	125 (22%)	61 (26%)	186 (23%)	287 (48%)	187 (62%)	474 (53%)	
	<i>25+</i>	434 (76%)	183 (74%)	617 (75%)	306 (52%)	113 (38%)	419 (47%)	
Pancreas transplant								
	<i>Yes</i>	156 (27%)	52 (21%)	208 (25%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	<0.0001
HbA1c (%)								
	<i>Mean (SD)</i>	7.7 (1.9)	7.9 (2.0)	7.8 (1.9)	7.4 (1.1)	7.5 (1.3)	7.5(1.2)	
	without pancreas transplant	<i>Mean (SD)</i> 8.3 (1.5)	8.4 (1.8)	8.4 (1.6)*	7.4 (1.1)	7.5 (1.3)	7.5 (1.2)	0.0001
	with pancreas transplant	<i>Mean (SD)</i> 6.0 (1.7)	6.0 (2.0)	6.0 (1.7)*				
Insulin Regimen								
	<i>Single shot</i>	43 (9%)	15 (7%)	58 (8%)	31 (5%)	12 (4%)	43 (5%)	<0.0001
	<i>Multiple</i>	318 (67%)	150 (68%)	468 (67%)	333 (57%)	145 (49%)	478 (54%)	
	<i>Pump</i>	103 (22%)	53 (24%)	156 (23%)	214 (36%)	139 (47%)	353 (40%)	
	<i>Other</i>	9 (2%)	3 (1%)	12 (2%)	11 (2%)	2 (1%)	13 (1%)	
Dose (Units/Kg/Day)								
	<i>Mean (SD)</i>	0.5 (0.3)	0.6 (0.3)	0.5 (0.4)	0.6 (0.2)	0.6 (0.2)	0.6 (0.2)	0.053
Other Autoimmune diseases								
	<i>Yes</i>	110 (19%)	34 (14%)	144 (18%)	126 (21%)	66 (22%)	192 (22%)	0.043

* p < 0.0001, for cases without pancreas transplants compared with those who had transplants

Table 4: Related Characteristics at enrollment according to study group.

Characteristic		Case			Control			P value
		Singleton	Trio Proband	Total	Singleton	Trio Proband	Total	Total Cases vs. Total Controls
Hypertension								
	<i>Yes</i>	482 (85%)	204 (82%)	686 (84%)	43 (7%)	11 (4%)	54 (6%)	<0.0001
Antihypertensive treatment								
	<i>Yes</i>	468 (83%)	203 (83%)	671 (83%)	NA	NA	NA	<0.0001
Blood Pressure								
Systolic BP (mm Hg)	<i>Mean (SD)</i>	131.1 (20)	129.7 (18)	130.7 (19)	118.5 (12)	115.7 (11)	117.6(12)	<0.0001
Diastolic BP (mm Hg)	<i>Mean (SD)</i>	74.1 (11.0)	75.1 (10.6)	74.4 (10.9)	71.4 (8.1)	71.3 (8.3)	71.4 (8.1)	<0.0001
Serum Lipids								
Total Cholesterol (mg/dL)	<i>Mean (SD)</i>	188.3 (47)	199.6 (44)	191.6 (46)	185.1 (31)	186.5 (34)	185.5 (32)	0.029
HDL Cholesterol (mg/dL)	<i>Mean (SD)</i>	53.3 (18.0)	56.2 (16.6)	54.1 (17.6)	59.0 (15.9)	56.6 (14.7)	58.2 (15.5)	<0.0001
Lipid-lowering drug	<i>Yes</i>	302 (53%)	149 (60%)	451 (55%)	500 (85%)	251 (85%)	751 (85%)	<0.0001
Parents' Living								
	<i>0</i>	180 (32%)	0	180 (22%)	119 (20%)	0	119 (13%)	<0.0001*
	<i>1</i>	208 (37%)	0	208 (26%)	182 (31%)	0	182 (21%)	
	<i>2</i>	159 (28%)	247 (100%)	404 (50%)	258 (44%)	303 (100%)	559 (63%)	
	<i>Unkonwn</i>	14 (3%)	0	14 (2%)	26 (4%)	0	26 (3%)	

* Note: The Chi-square test is done by comparing the numbers of parents' living of case and control singletons.

Table 5: Other Complications of Diabetes according to study group*

Complication		Case			Control			P value
		Singleton	Trio Proband	Total	Singleton	Trio Proband	Total	Total Cases vs. Total Controls
Retinopathy								
Laser Treatment	<i>Yes</i>	476 (86%)	201 (83%)	677 (85%)	109 (19%)	40 (13%)	149 (17%)	<0.0001
Cardiovascular Disease								
	<i>Yes</i>	504 (89%)	206 (83%)	710 (87%)	67 (11%)	27 (9%)	94 (11%)	<0.0001
Neuropathy								
	<i>Yes</i>	383 (67%)	156 (63%)	539 (66%)	81 (14%)	23 (8%)	104 (12%)	<0.0001

*The complications are self-reported.